Literature DB >> 19941744

Diabetes mellitus is associated with high early-mortality and poor prognosis in patients with autoimmune hemolytic anemia.

Hideki Nakasone1, Shinichi Kako, Hiroshi Endo, Ayumu Ito, Miki Sato, Kiriko Terasako, Shinya Okuda, Yukie Tanaka, Rie Yamazaki, Kumi Oshima, Aki Tanihara, Michiko Kida, Takakazu Higuchi, Koji Izutsu, Junji Nishida, Akio Urabe, Kensuke Usuki, Yoshinobu Kanda.   

Abstract

The incidence of autoimmune hemolytic anemia (AIHA) is highest among the elderly, and thus it is frequently associated with co-morbidities such as diabetes mellitus (DM). However, there have been few reports on the impact of these co-morbidities on survival in patients with AIHA. Therefore, we retrospectively reviewed the records of 53 consecutive AIHA patients and assessed the impact of DM on survival. Eighteen of the 53 patients had DM. The estimated 4-year overall survival (4y-OS) for all patients was 84.9%. Infection was the most frequent cause of death, and fatal infections were exclusively observed in patients with DM. The deaths in DM patients occurred frequently within 1 year, to give significantly poor survival (4y-OS; 69.3% versus 93.6%, P=0.0064). The presence of DM was identified as the only significant risk factor for survival. A large prospective investigation is warranted to assess the impact of co-morbidities on survival in patients with AIHA.

Entities:  

Mesh:

Year:  2009        PMID: 19941744     DOI: 10.1179/102453309X12473408860262

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  3 in total

Review 1.  Autoimmune hemolytic anemia.

Authors:  Anita Hill; Quentin A Hill
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.

Authors:  Quentin A Hill; Anita Hill; Sigbjørn Berentsen
Journal:  Blood Adv       Date:  2019-06-25

3.  Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow-up.

Authors:  Dennis Lund Hansen; Sören Möller; Henrik Frederiksen
Journal:  Eur J Haematol       Date:  2022-03-19       Impact factor: 3.674

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.